The London Pensions Fund Authority (LPFA) has appointed GlaxoSmithKline director of global pension investments Robert Vandersluis as a non-executive director to its board.
Figures from the LPFA's annual report 2013 showed the fund grew by £427m to £4.6bn between 2012 and 2013. Its valuation also revealed its funding level was around 95% (PP Online, 8 May). LPFA ch...
To continue reading this article...
Join Professional Pensions
Signup and gain exclusive members-only insights
- Unlimited access to real-time news, analysis and opinion from the industry
- Receive our in-depth monthly magazine in either print or digital format
- Access our Sustainable Investment Hub covering news and opinion from thought leaders in the ESG space
- Receive important and breaking news stories selected by the Editors in our daily newsletter
- Hear from industry experts and other forward-thinking leaders
- Receive a monthly members-only newsletter with exclusive opinion pieces from leading industry experts and a feature from the magazine in advance of its release date
